Annual report pursuant to Section 13 and 15(d)

Intangibles (Tables)

v3.19.1
Intangibles (Tables)
 12 Months Ended
Dec. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Finite-Lived Intangible Assets
The table below provides a summary of the JMC intangible asset as of December 31, 2018 and 2017, respectively:
 
($ in thousands)
 
Estimated Useful
 
 
 
 
 
 
 
 
 
Lives (in years)
 
 
2018
 
 
2017
 
Ceracade®
 
 
3
 
 
$
300
 
 
$
300
 
Luxamend®
 
 
3
 
 
 
50
 
 
 
50
 
Targadox®
 
 
3
 
 
 
1,250
 
 
 
1,250
 
Exelderm®
 
 
3
 
 
 
1,200
 
 
 
0
 
Total
 
 
 
 
 
 
2,800
 
 
 
1,600
 
Accumulated amortization
 
 
 
 
 
 
1,383
 
 
 
717
 
Net intangible assets
 
 
 
 
 
$
1,417
 
 
$
883
 
 
 
 
 
 
 
 
Schedule of Acquired Finite-Lived Intangible Assets by Major Class
The table below provides a summary for the years ended December 31, 2018 and 2017, of JMC recognized expense related to its product licenses, which was recorded in costs of goods sold on the Consolidated Statement of Operations (see Note 18):
 
(
$ in thousands)
 
 
 
 
Intangible assets at 
January 1, 2017
 
$
1,417
 
Addition
 
 
–
  
Amortization expense
 
 
(534
)
Intangible assets at December 31, 2017
 
$
883
 
Addition
 
 
1,200
 
Amortization expense
 
 
(666
)
Intangible assets at December 31, 2018
 
$
1,417
 
 
 
 
 
 
 
 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense
The future amortization of these intangible assets is as follows ($ in thousands):
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total
 
 
 
Ceracade®
 
 
Luxamend®
 
 
Targadox®
 
 
Exelderm®
 
 
Amortization
 
Year Ended December 31, 2019
 
$
33
 
 
$
4
 
 
$
313
 
 
$
400
 
 
$
750
 
Year Ended December 31, 2020
 
 
–
  
 
 
–
  
 
 
–
  
 
 
400
 
 
 
400
 
Year Ended December 31, 2021
 
 
–
  
 
 
–
  
 
 
–
  
 
 
267
 
 
 
267
 
Total
 
$
33
 
 
$
4
 
 
$
313
 
 
$
1,067
 
 
$
1,417